Drreddys Laboratories | RDY - Sales Revenues


Drreddys Laboratories reported INR87.27B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
ANI Pharmaceuticals USD 227.81M 16.44M Sep/2025
Aurora Cannabis CAD 90.37M 7.65M Sep/2025
Bayer EUR 9.66B 1.08B Sep/2025
Canopy Growth CAD 66.68M 5.45M Sep/2025
Cipla INR 75.18B 710M Dec/2025
Corcept Therapeutics USD 207.6M 13.2M Sep/2025
Drreddys Laboratories INR 87.27B 1.82B Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Hikma Pharmaceutical USD 829M 758M Jun/2025
Lonza CHF 3.58B 63M Jun/2025
Novartis USD 13.91B 144M Sep/2025
Pacira USD 179.52M 1.58M Sep/2025
Prestige Brands USD 283.44M 9.34M Dec/2025
Richter Gedeon HUF 214.69B 2.04B Sep/2025
Sun Pharmaceuticals INR 147.99B 3.21B Dec/2025
Supernus Pharmaceuticals USD 192.1M 26.6M Sep/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025